SCHEMBL4279716

SCHEMBL4279716

CC(C)COc1ccc(C(=O)c2ccc(OCC(C)C)c(CC(=O)O)c2)c(OCC(C)C)c1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FOS P01100 2/20 0.63
▸ JUN P05412 2/20 0.63
▸ ALDH1A1 P00352 2/20 0.46
▸ HIF1A Q16665 1/20 0.46
▸ HSD17B10 Q99714 1/20 0.43
▸ MAPT P10636 4/20 0.42
▸ PKM P14618 1/20 0.42
▸ TSHR P16473 1/20 0.42
▸ HTT P42858 1/20 0.42
▸ MAPK1 P28482 1/20 0.40
▸ THRB P10828 1/20 0.40
▸ NPC1 O15118 1/20 0.40
▸ NR1H4 Q96RI1 4/20 0.39
▸ PTGER1 P34995 1/20 0.39
▸ SRD5A2 P31213 1/20 0.39
▸ POLB P06746 2/20 0.38
▸ HPGD P15428 1/20 0.38
▸ XBP1 P17861 1/20 0.38
▸ XDH P47989 1/20 0.38
▸ SLC22A12 Q96S37 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4279655 0.94 FOS (0.56) FOSJUNALDH1A1HIF1AHSD17B10
SCHEMBL4276620 0.88 JUN (0.81) FOSJUNALDH1A1HIF1AMAPT
SCHEMBL4291381 0.88 FOS (0.55) FOSJUNALDH1A1HIF1AMAPT
SCHEMBL28747839 0.86 FOS (0.53) FOSJUNALDH1A1HIF1AHSD17B10
SCHEMBL4278603 0.86 FOS (0.57) FOSJUNALDH1A1HIF1AMAPT
SCHEMBL4289803 0.84 FOS (0.54) FOSJUNALDH1A1HIF1AHSD17B10
SCHEMBL4279733 0.83 FOS (0.54) FOSJUNALDH1A1MAPTTSHR
SCHEMBL4279133 0.83 FOS (0.49) FOSJUNALDH1A1HIF1AHSD17B10
SCHEMBL4286099 0.83 FOS (0.52) FOSJUNALDH1A1HIF1AHSD17B10
SCHEMBL4278045 0.82 JUN (0.64) FOSJUNALDH1A1HIF1AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090118169-A1 NOVEL COMPOUNDS AND PHARMACEUTICAL USE THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-05-07 — — US disclosed
US-20090118169-A1 NOVEL COMPOUNDS AND PHARMACEUTICAL USE THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-05-07 — — US disclosed
US-20090118169-A1 NOVEL COMPOUNDS AND PHARMACEUTICAL USE THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-05-07 — — US disclosed
US-7314888-B1 Compounds and medicinal use thereof TOYAMA CHEMICAL CO., LTD. (JP) 2008-01-01 — — US disclosed
US-7314888-B1 Compounds and medicinal use thereof TOYAMA CHEMICAL CO., LTD. (JP) 2008-01-01 — — US disclosed
CN-1325376-A Novel compound and medical use thereof TOYAMA CHEMICAL CO LTD (JP) 2001-12-05 — — CN disclosed
EP-1127869-A1 NOVEL COMPOUNDS AND MEDICINAL USE THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2001-08-29 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090118169-A1 NOVEL COMPOUNDS AND PHARMACEUTICAL USE THEREOF SP1, AP1G1, AP1M1 FOS 63/4885JUN 20/4885ALDH1A1 2031/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback